1-amino-1-phenylmethylphosphinic acid | 126529-62-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-amino-1-phenylmethylphosphinic acid
• 英文别名: (aminophenylmethyl)phosphinic acid；[Amino(phenyl)methyl]phosphinic acid
• CAS: 126529-62-2
• 化学式: C₇H₁₀NO₂P
• 分子量: 171.136
• InChiKey: JLTNHFQJNQZJTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-amino-1-phenylmethylphosphinic acid 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 28.0h， 生成 benzyl N-[[methoxy(oxido)phosphaniumyl]-phenylmethyl]carbamate
  参考文献：
  名称：

  双α-氨基烷基次膦酸盐的简便合成

  摘要：

  摘要 在此，我们报告了通过在回流苯中将 Cbz 保护的氨基酸甲酯的次膦酸类似物添加到适当的亚胺中获得的双-α-氨基烷基次膦酸的酯的简便合成。通过在乙酸中的 30% HBr 的作用，可以一步实现酯的完全脱保护。

  DOI：

  10.1080/00397910600767330
• 作为产物：
  描述：

  苯甲醛肟 在 亚膦酸 作用下， 以 异丙醇 为溶剂， 反应 72.0h， 以56.5%的产率得到1-amino-1-phenylmethylphosphinic acid
  参考文献：
  名称：

  芳族氨基酸的次膦酸和膦酸类似物的合成

  摘要：

  芳基和芳烷基醛肟与次磷酸反应生成氨基次膦酸，氨基次膦酸被氧化成相应的氨基膦酸。

  DOI：

  10.1007/bf02495362

文献信息

• (&agr;-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof
  申请人：Institut National de la Sante et de la Recherche Medicale (Inserm)

  公开号：US06518260B1

  公开（公告）日：2003-02-11

  The invention concerns compounds derived from (&agr;-aminophosphino) peptides, of general formula (I), in which R1 and R2 each represents a hydrogen atom or taken together form an imine with the adjacent nitrogen atom; R3 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally, a methyl group substituted by a heterocyclic, aromatic or saturated group; R4 represents a phenyl group, a benzyl group, these groups capable of being substituted or not, a hydrogen atom, an alkyl group, analkenyl group or a cycloalkyl group; R5 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl, cycloalkylmethyl group or finally a methyl group substituted by a heterocyclic, aromatic or saturated group; R6, R7 and R8 can in particular represent a hydrogen atom, an alkyl group, a phenyl group substituted or not . . . n is equal to 0 or 1, in the form of enantiomers, diastereoisomers or racemic mixtures, their salts, their method of preparation and their therapeutic applications.

  该发明涉及从(&agr;-氨基膦)肽衍生的化合物，其一般式为(I)，其中R1和R2分别表示氢原子或与相邻氮原子形成亚胺；R3表示烷基、烯基、苯基、苄基，所有这些基团均可被取代或不取代，氢原子、环烷基、环烷基甲基基团或最后，被杂环、芳香或饱和基团取代的甲基基团；R4表示苯基、苄基，这些基团可被取代或不取代，氢原子、烷基、烯基或环烷基；R5表示烷基、烯基、苯基、苄基，所有这些基团均可被取代或不取代，氢原子、环烷基、环烷基甲基基团或最后，被杂环、芳香或饱和基团取代的甲基基团；R6、R7和R8可以特别表示氢原子、烷基、苯基取代或不取代... n等于0或1，以对映异构体、非对映异构体或混合物的形式存在，它们的盐、制备方法和治疗应用。
• AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN
  申请人：Roques Bernard

  公开号：US20110124601A1

  公开（公告）日：2011-05-26

  The present invention relates to a compound of the following general formula (I): R 1 —NH—CH(R 2 )—P(═O)(OR 3 )—CH 2 —C(R 4 )(R 5 )—CONH—CH(R 6 )—COOR 7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R 1 represents a —C(═O)—O—C(R 8 )(R 9 )—OC(═O)—R 10 group; R 2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R 3 represents a hydrogen atom or a —C(R 12 )(R 13 )—OC(═O)—R 14 group; R 4 and R 5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R 4 represents a hydrogen atom and R 5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R 6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R 7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe—COOR 18 , —CHR 19 —OC(═O)OR 20 and —CHR 19 —OC(═O)OR 20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.

  本发明涉及以下通式（I）的化合物：R1—NH—CH（R2）—P（═O）（OR3）—CH2—C（R4）（R5）—CONH—CH（R6）—COOR7或其药学上可接受的盐、异构体或任意比例的异构体混合物，特别是对映体混合物，尤其是外消旋混合物，其中R1代表—C（═O）—O—C（R8）（R9）—OC（═O）—R10基团；R2代表可选取代的碳氢链、芳基或杂环芳基基团或被杂环取代的亚甲基基团；R3代表氢原子或—C（R12）（R13）—OC（═O）—R14基团；R4和R5与承载它们的碳原子一起形成饱和碳氢基环或可选取代的哌啶环或R4代表氢原子，R5代表可选取代的苯基或苄基、杂环芳基环或被杂环取代的亚甲基基团；R6代表可选取代的碳氢链或可选取代的苯基或苄基；R7代表氢原子或苄基、烷基、杂环芳基、烷基杂环芳基、—CHMe—COOR18、—CHR19—OC（═O）OR20和—CHR19—OC（═O）OR20基团。本发明还涉及这些化合物作为药物的用途，特别是用于疼痛治疗，更有利的是神经病理性和神经炎性疼痛的治疗，以及它们的合成方法和含有它们的组合物。
• A Novel Synthetic Route to 1-Aminoalkylphosphinic Acids
  作者：Xian-Yun Jiao、Christophe Verbruggen、Marianne Borloo、Willy Bollaert、Alex De Groot、Roger Dommisse、Achiel Haemers

  DOI：10.1055/s-1994-25395

  日期：——

  A "one-pot" synthesis of various 1-aminoalkylphosphinic acids is described. They were obtained in high yield by the deprotection of the corresponding bis(trimethylsilyl) N-tritylaminoalkylphosphites. The latter were prepared by addition of bis(trimethylsilyl) phosphonite to a Ntritylalkanimine.

  本研究描述了各种 1-氨基烷基膦酸的 "一步法 "合成。通过对相应的双（三甲基硅基）N-三苯甲基氨基烷基膦酸进行脱保护，可以获得高产率的 1-氨基烷基膦酸。后者是通过将双（三甲基硅基）亚磷酸加到 N-三苯甲基烷基氨基中制备的。
• Multiple solid phase synthesis of (RS)-1-aminophosphinic acids
  作者：E.Andrew Boyd、Weng C. Chan、Vincent M. Loh

  DOI：10.1016/0040-4039(96)00082-2

  日期：1996.3

  Novel resin bound (RS)-1-aminophosphinic acids, prepared by the facile addition of bis(trimethylsilyl)phosphonite to 9-aryl or alkylimino-xanthen-3-yloxymethyl polystyrene, on acidolysis afforded (RS)-1-aminophosphinic acids in high yields and purities.

  新型树脂结合的（RS）-1-氨基次膦酸，是通过将双（三甲基甲硅烷基）亚膦酸酯容易地加成到9-芳基或烷基亚氨基-黄嘌呤-3-基氧基甲基聚苯乙烯上而制得的，可在高酸度下得到（RS）-1-氨基次膦酸产量和纯度。
• Phosphonic acid derivative having inhibitory activity against carboxypeptidase B
  申请人：Meiji Seika Kaisha Ltd.

  公开号：US20030119787A1

  公开（公告）日：2003-06-26

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: 1 wherein R 1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R 2 and R 3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH 2 —, —O—, or —NH—; A represents the following group (II): 2 [in which R 7 and R 8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R 9 and R 10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  以下是通用式（I）及其药学上可接受的盐所代表的化合物：其中R1代表氢原子、烷基、取代烷基等；R2和R3代表氢原子、烷基、取代烷基、烷氧基等；X代表—CH2—、—O—或—NH—；A代表以下基团（II）：其中R7和R8代表氢原子、烷基、酰基、烷氧羰基等；R9和R10代表氢原子、卤素原子、羟基、苯基、烷基等；E代表氢原子等，具有对羧肽酶B的抑制活性，可用于治疗和/或预防血栓性疾病。